SW203668

Cat. No.:	HY-124084
CAS No.:	1673556-40-5
Molecular Formula:	$C_{22}H_{19}N_3O_2S$
Molecular Weight:	389.47
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SW203668 is a benzothiazole compound, shows anti-tumor activity against lung cancer cell lines (IC_{50}=0.022-0.116 μM)[1].
In Vitro	SW203668 (0.1, 0.3, 1, 3, and 10 μM) has 2 benzothiazole enantiomers, while (+)-SW203668 is more potent competitor to bind p37/p30 than (-)-SW203668[1]. SW203668 (1 nM-10 μM; 2 d) inhibits H2122 cells growth with IC_{50}s of 0.029 μM ((+)-SW203668) and 0.007 μM ((-)-SW203668), respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SW203668 (25 mg/kg; i.p.; single dose) shows a half-life of 8 h in mouse plasma and (6 mg/kg, 20 mg/kg; i.p.; once daily for 15 d) has low toxicity in CD-1 mice[1]. SW203668 (20 mg/kg; i.p.; once daily for 14 d) preserves sebocytes and significantly increases the number of sebocytes in mice[1]. SW203668 (20 mg/kg; i.p.; once daily for 14 d) shows antitumor efficacy in dosing immunodeficient nonobese diabetic severe combined immunodeficiency (NOD-SCID) mice harboring an H2122 cell-derived tumor xenograft[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Theodoropoulos PC, et al. Discovery of tumor-specific irreversible inhibitors of stearoyl CoA desaturase. Nat Chem Biol. 2016 Apr;12(4):218-25.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA